EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

November 16, 2026

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 87 min

Earnings Call Speaker Segments

Andrea Cangioli

executive
#1

Thank you so much, Nicola. Thanks to Bianca, and thanks as well to Enrico Romagnoli, who, as he always does, is keeping this call running alongside me. Good afternoon to all of you, and I appreciate everyone joining us today. It is genuinely a pleasure to walk you through the El.En. Group's results for the first nine months of 2026. Right from the outset, let me say we are highly pleased; the numbers are excellent, and they arrive in a year when El.En. has also reshaped itself, becoming a more focused company, a more profitable one, and one better positioned for what lies ahead. I will begin with the two figures that capture this period best. Consolidated revenue across the first nine months came to EUR 363 million, which is 7.6% higher than the corresponding stretch of 2025. Early in the year, we informed the market that we were looking for growth beyond 5%. We now sit comfortably ahead of that goal, and we feel confident that this will remain the case through year-end. The second figure is operating income, EBIT, which came in at EUR 67.9 million, roughly 33% above last year. What that means is our operating margin has climbed from 15.2% to 18.7% of revenue. When we laid out our guidance, our ambition involved not just growing EBIT in absolute terms but also raising its share of revenue. We're able to report today that the target has been reached. The third quarter on its own demonstrates this. Revenue continued to grow, and operating income for the quarter increased by about 25% compared with a year earlier, with a margin exceeding 20%. So this isn't a result pieced together from a single strong month or a single strong quarter. It mirrors a steady and consistent progression throughout the entire year. In the next few minutes, I'd like to give you a fuller account of where these results come from and what they say about the company we've become, and again, to convey our confidence in what lies ahead. Let me be very clear on one point. Part of the gain in our EBIT margin reflects the group's new scope, and I'll cover that shortly. What you're seeing isn't just a mathematical side effect of a different perimeter. It comes from decisions and from work that began years back. The products driving our growth now didn't appear overnight. Each one results from a lengthy, rigorous process: the original idea, development in our labs, refinement together with physicians and key opinion leaders, industrialization, and certification for sale in markets worldwide. Today we're collecting the benefits of that long journey, and we're both happy and proud that the result is so satisfying. Beside innovation, we have pursued efficiency with just as much determination. In recent months, our teams ran a thorough and methodical effort aimed at lowering the cost of the products we sell, addressing design, sourcing, and production processes. Along with a more favorable product mix, that raised the quality of our margins. Operating leverage exists. When revenue rises while the cost structure stays controlled, we know that a bigger portion of every additional euro in sales converts into profits. That is precisely what is occurring in our medical business right now, and it is one reason operating income is increasing far more rapidly than revenue. To put it simply: a strong R&D pipeline that has produced outstanding products over many years, disciplined cost control, and top-line growth that enhances profitability. Those are the pillars behind the results we're sharing today, and those pillars are firm. Let me now turn to an important milestone. We completed the sale of 80% of Cutlite Penta, our laser cutting business, to TRUMPF Group on November 5. TRUMPF stands as a global leader in industrial lasers and machine tools. By joining forces with TRUMPF, Cutlite Penta gains access to a worldwide commercial and service network along with world-class industrial expertise. This is a great home for the business and for the people who built it. Holding onto a 20% stake for several years will let us continue backing Cutlite Penta's expansion through a long-term industrial partnership. This deal wraps up a journey that began last year when we sold our Chinese cutting operations, Penta Laser Zhejiang. We chose that route since, in laser cutting, the laser source has become a commodity. It gets bought from third-party suppliers; in such a market, our core strength — designing and controlling the laser technology at the heart of our system — no longer provided an edge. And in areas where we don't control the key technologies, it grows tougher for us to generate the value and the profitability that define our group. The El.En. What comes out of that process is a company that's clearer and stronger. Right now, medical makes up roughly 92% of our revenue, and the industrial operations we've kept are precisely the ones where we have complete command of the core technologies: laser marking, medium-power CO2 laser sources, and cultural heritage preservation. Put differently, we've decided to focus our energy, our talent, and our investments on the areas where we're genuinely distinctive, and we're confident this is the correct decision for our customers and for our people, and as a result for our shareholders. At present, the medical sector is meeting our highest expectations. This is fueling expansion across the entire group, thanks to solid results in its core segments and outstanding performance overall. I'll start with aesthetics, which is our biggest segment. In this market, anti-aging technologies remain the preferred choice, and our group holds a genuinely strong competitive stance in that space, owing to the range and the innovation of what we offer. Onda PRO, the microwave system from DEKA for body treatments, continues to produce excellent outcomes. Onda PRO builds on the original Onda, designed to address a market that is increasingly centered on skin tightening and firming. A lot of competitors have tried to copy what we've done—some have even produced direct replicas—and our sales organization and legal departments are putting in serious effort to safeguard both our customers and our brand. To my mind, nothing could demonstrate more clearly just how much our innovation is worth. Our minimally ablative CO2 technology remains the gold standard for facial rejuvenation, delivered through DEKA's Tetra PRO and HELIX as well as Quanta System's newest laser, MT. Meanwhile, DEKA's RedTouch PRO and Asclepion's YellowStar are making headway too, built on a different technological approach; when it comes to ultra-short pulse lasers, Quanta System's Discovery Pico stands as the reference point for tattoo removal and skin toning, and Quanta's Chrome alongside DEKA's newly launched TORO systems are seeing outstanding results. Another point I want to emphasize is the direct distribution we have in the German-speaking countries, which Asclepion operates; it has established productive networks that today also sell particular DEKA and Quanta System products. That approach is delivering excellent results. In surgery, performance is especially robust. Urology serves as the primary growth engine. Our installed base continues to expand, aided this year by Quanta System's new U.S. distribution hub going live, which is off to a very strong beginning. Our CO2 platforms for ENT and gynecology are also doing well.

Andrea Cangioli

executive
#2

Every urology system we install also drives demand for our sterile optical fibers, both single-use and multiple-use versions. That recurring revenue stream now makes up more than 50% of our medical service business. As time passes, it renders our results more stable and simpler to forecast. To support this growth, Quanta System is building an additional, larger clean room in Samarate that will focus on fiber production. Finally, some comments on our multi-brand strategy. DEKA, Quanta System, Asclepion, and ASA all keep separate identities, technologies, brands, and distribution channels, while sharing research and knowledge across the group. Beyond that, we're bringing them closer together where it’s logical—Italy being one example, where DEKA, Quanta System, and Asclepion are combined under the Renaissance brand as a single organization, or in the DACH region—Germany, Austria, and German-speaking Switzerland—as I mentioned earlier. That balance of autonomy and collaboration is one of the things that drives our success. Looking at it geographically, our expansion this year has a clearly global flavor. More than half our revenue is generated outside Europe, and those are the markets where we've seen the most momentum. The United States is particularly notable. The U.S. is the largest medical and aesthetic technology market anywhere, the biggest single market globally, and this year we've considerably expanded our footprint there, chiefly via Quanta System's new direct distribution in urology. South America and the Far East also delivered outstanding results. Those regions are vibrant markets where demand for aesthetic and medical treatments keeps climbing, and our brands are gaining growing recognition for quality, reliability, and innovation. We're especially proud of what we've achieved in South Korea, which today is seen as the aesthetic sector's most essential market — the source of the finest innovation in both technologies and cosmetic treatments. The fact that we hold a leading position in a country drawing so much attention speaks volumes about how strong our market position is. Our geographic balance is a strength in its own right. It ensures that growth isn't dependent on one market alone, and that we're able to capture opportunities as they emerge while cushioning the effects of short-term downturns in particular regions. A clear illustration is the soft market in the Gulf area. That region fueled revenue growth in the recent past. Revenue fell there in 2026, yet the overall result was unaffected; our response is to increase marketing support in this area. To give you one illustration, just this past weekend we were side by side with—we stood together with—our distributors from Egypt, Iraq, Jordan, and Libya at a promotional event held at a luxury resort in Marsa Alam, Egypt, on the Red Sea, for this country's end users, who came in large numbers to attend this great event. After leaving laser cutting, our industrial operations are now focused on three areas: marking, laser sources, and restoration. In marking, LASIT supplies systems for identification and traceability, mainly on small surfaces. Ot-las, which is also active in marking, builds systems for decoration and technical processing of large surfaces across a wide range of materials. El.En. It builds custom systems, often centered on the company's own mid-power CO2 lasers, which are themselves a distinct business line. Ot-las and El.En.'s industrial division each posted higher revenue for the period, along with better results — I'm glad to share that. Manufacturers, especially in Europe, are going through a tough stretch, and our industrial segment feels that too. One signal stands out as very encouraging: after-sales service and components are growing fast, in both volume and their portion of revenue. A large number of customers pick us for how well we serve them, which is a strong vote of confidence in the value we provide. Next comes restoration—a modest division that gives us a great deal of pride. Revenues from our laser systems used to preserve cultural heritage continue to rise, and that includes rental and consulting services. Beyond that, on the bottom line—which we care about more—these technologies keep delivering remarkable outcomes in bringing significant artworks back to health, as we are pleased to announce from time to time. Once again this business shows how adaptable laser technology is and how our group can uncover valuable new uses for it. If any single quality defines El.En., it is innovation. Each year research and development consumes considerable resources, most of all in the highly skilled personnel who staff our technical and research departments. They work closely alongside our commercial teams and with management to turn market needs into new products within the tight timelines that today's market demands. Our group ranks among the very few players globally that can develop, produce, and sell systems built on such a broad range of laser technologies — solid state, semiconductor, fiber, dye, and CO2 laser — as well as frequency conversion systems covering the entire spectrum from infrared to ultraviolet. In addition to lasers, we work with other forms of energy, such as radio frequency, microwaves, and high-intensity electromagnetic fields. Let me share a few examples of what is emerging from our labs today. During the quarter in surgery, we finished work on a new 445 nm blue laser, which works in outpatient settings for smaller procedures as well as in the operating room for ENT procedures using a fiberscope. We're also working on a next-generation CO2 surgical system featuring a hybrid arm and fiber setup plus automated micromanipulators for ENT, aimed at making surgery more precise and simpler to carry out. On the dermatology side, we're building a new platform with three wavelengths for benign pigmented lesions, tattoo removal, and skin rejuvenation, backed by scientific research into how light moves through tissue. The early results appear very encouraging. Drawing on what we learned from RedTouch and RedTouch PRO, we're likewise far along in developing a new high-power platform aimed at vascular reasons. New applicators and new applications, the face included, keep moving our Onda microwave technology forward. Tomorrow's products are these projects. They're the ones that will carry our growth through the years ahead, much as the investment made in the past year is carrying it right now. Nothing I've talked about could happen without our people. Quality, passion, and commitment on their part form our single most important competitive advantage. My sincere thanks go to every one of them; we're also still making genuine headway on sustainability. Our internal control system and our supply chain monitoring have both been strengthened. We continue putting money into our people, and our emissions are coming down. Broadly, our sustainability plan is on track, and in certain areas it runs ahead of schedule, particularly when it comes to shifting toward renewable energies; as a matter of fact, our 2030 targets for Scope 2 emissions have already been met well ahead of time; that's the reason we're now setting new goals with greater ambition, which for the first time would cover Scope 3 emissions too, those along our value chain. Last, our financial position.

Andrea Cangioli

executive
#3

Our financial footing is still very strong, and net financial position got even better over the period, even while we paid out dividends, kept putting money into our plants, and backed the expansion of the business, which includes launching our new urology distribution hub in the U.S. Thanks to the proceeds from the Cutlite Penta transaction, our financial position is going to strengthen even more. The biggest drain on cash during the period was net working capital. Even so, the ratio of net working capital to trailing last 12 months revenues at September 2026 stood below where it was at September 2025, and we expect to bring that ratio down further over the final months of the year. This solidity is a major strength; it gives us the freedom to keep investing in organic growth, which stays our priority, in new products, new markets, and new production capacity, as we are doing in Calenzano and Samarate; it lets us weigh new opportunities with calm and confidence. That covers the opening portion of my remarks. Please, Enrico, go ahead with your section.

Enrico Romagnoli

executive
#4

Thank you, Andrea, and good morning, everyone. As I typically do, I'll give a brief overview of the nine-month financial results that the Board of Directors approved and that we released last Friday. Just as with the half-year report, these figures follow the IFRS 5 accounting standard. The contribution from Cutlite Penta's laser cuttings business is treated as a discontinued operation, for both 2026 and the 2025 comparative period. As is customary for the quarterly report, the income statement runs down to pre-tax income. Group revenue for the first nine months of 2026 came in at EUR 363 million, a rise of 7.6% over the EUR 337.5 million recorded in the same period of 2025, and still ahead of our guidance of more than 5% growth. The medical sector, which now accounts for over 92% of revenue, was up 8.9% at EUR 335 million, whereas the remaining industrial sector fell 6.4% to EUR 28 million; across the nine months, weakness in the US dollar weighed on revenue growth by roughly 0.7%, or EUR 2.3 million. Gross margin came to EUR 183.2 million, an increase of 11.9% from EUR 163.6 million as of September 2025. As a share of revenue, that figure rose by a full two points, moving from 48.5% up to 50.5%, which reflects a better product mix, supported by medical's increasing contribution as well as the targeted steps we took to bring down cost of goods sold. Operating expenses came to EUR 39 million, essentially flat compared with the EUR 38.1 million recorded in 2025, and as a percentage of revenue they fell from 11.3% to 10.7%. Staff costs reached EUR 68 million, a 2.4% increase over the EUR 66.4 million posted in 2025, and their share of revenue also decreased. EBITDA was EUR 76.2 million, 29% higher than the EUR 59.1 million in 2025. The EBITDA margin improved to 21% from 17.5%. Depreciation, amortization, and provision came to EUR 8.4 million, compared with EUR 7.9 million in 2025, and the incidence on revenue held steady at 2.3%. This reflects the combined effect of greater depreciation and risk provisions, partially offset by a reduced provision for credit risk. EBIT reached EUR 67.9 million, a 32.6% increase from EUR 51.2 million in the first nine months of 2025, while the EBIT margin climbed from 15.2% to 18.7%. As I noted in September, presenting the income statement under IFRS 5 carries, purely as an accounting technique matter, a penalty to EBIT of about EUR 2.3 million. Excluding that, nine-month EBIT would have come in at roughly EUR 70 million. This cost is offset by income of the same amount, recorded mainly in the result from discontinued operations, so the accounting technique has no effect on the net result. Net financial income was EUR 2.7 million, compared with a net charge of EUR 1.1 million in the same period last year. That improvement largely reflects the exchange difference, which swung from a loss of EUR 3.4 million in September 2025 to a gain of EUR 0.4 million in the current period. The rest of it comes from return on the group's liquidity, which is invested in short and medium-term financial instrument. Other income and expenses include our share of the result from an associated company, which came in at negative EUR 0.9 million, driven mainly by losses at Penta Laser Zhejiang and Withus — the two businesses whose majority stakes we sold in 2025. In addition, EUR 0.9 million relates to the full impairment of the investment in Epica International, which was already booked in the first half of the year. Pretax income reached EUR 68.8 million, a 40% increase from EUR 49 million as of September 2025. Although, as usual, we're not reporting the figures below pretax income, the result from discontinued operations as of September is negative EUR 4.7 million, and it consists of three components. Okay, so first, we have the net loss from the cutting business over the nine-month period, which came to EUR 3.1 million, and EUR 3 million of that was recorded right in the third quarter. Then there's the extraordinary loss of EUR 3.9 million that was already booked back in June — that's the impairment bringing the carrying amount of the business in line with the estimated sales price we agreed with TRUMPF. And third, there's a positive piece of roughly EUR 2.3 million, which essentially mirrors the IFRS 5 penalty on EBIT that was mentioned earlier. That's the reason the IFRS 5 presentation doesn't affect the net result at all. If we apply a tax rate consistent with what we saw in the first half, then the group's net result — including the result from the discontinued operation — would come in roughly 16% higher than the first nine months of 2025, at EUR 41.8 million versus EUR 36 million for that same period in 2025. Had IFRS 5 not been applied, revenue for the first nine months would have reached EUR 432 million, which is a 2.4% increase over EUR 421.9 million in 2025. Under that configuration, the industrial sector would have seen a decline of 15.2%, since cutting revenue fell from EUR 85.2 million to EUR 69.2 million. Taking the cutting business into account as well, EBITDA rose 16.6% to EUR 76.5 million, while EBIT climbed 19.8% to EUR 65.9 million; the EBIT margin improved from 13% to 15.3%. For the third quarter on its own, revenue came in at EUR 116.5 million, a gain of 4.5%, as medical advanced roughly 6% and industrial declined roughly 11%, and the gross margin stood at 51.8% with an EBIT margin of 21% versus 17.6% in Q3 2025. Turning next to cash flow and the net financial position: the group's financial position stayed very solid. Over the nine months, our net financial position rose by roughly EUR 20 million — starting the year at EUR 172 million and reaching EUR 192 million by the end of September — and in the third quarter alone it went up by EUR 8 million. The chart makes clear that the largest drain on cash came from net working capital, which grew by about EUR 28 million. Within that figure, EUR 6 million relates to the rollout of the new Quanta System distribution hub for urology in the U.S., which generated close to EUR 12 million in revenue during the period. Capital expenditures were EUR 10.5 million, plus EUR 2.5 million in liquidity allocated to an insurance-style financial instrument—a medium-to-long-term liquidity vehicle. In May, the parent company and certain subsidiaries distributed dividends amounting to EUR 21.3 million. Finally, discontinued operations contributed a positive EUR 16 million, which reflects the elimination of the cutting business's financial debt from the net financial position as of December 2025. Turning to sales-based revenue growth across businesses, revenue increased within the core medical application segment. Aesthetic posted EUR 186.5 million, a gain of 8.5%, driven by anti-aging technologies. This occurred even with weakness in hair removal, due in part to the deceleration in the < >. Surgical was once again the strongest performer, rising 15.6% to EUR 70.2 million, chiefly on the system. Therapy was slightly lower, down 1.5%. Medical service climbed 3.5% to EUR 63.3 million. Over 1/2 of that revenue stems from the sterile optical fiber for urology, a recurring revenue stream, which is why Quanta System is constructing a new clean room in Samarate to boost production capacity. In the industrial sector, which no longer includes cutting, the system fell 16% and laser sources dropped 26%, while restoration rose 45%, all on a small base. After-sale service and components increased 25% to EUR 8.2 million and now account for 29% of industrial revenue. To round things out, revenue for the nine-month period came to EUR 69.2 million, compared with EUR 85 million in 2025. Let's now look at the split by region. On the medical side geographically, Italy was down 8%, driven largely by professional aesthetic, which had benefited from especially favorable conditions in 2025. Europe was essentially flat, with a solid result in Germany thanks to our direct presence. Markets outside Europe climbed 16.3%, with excellent performance in the U.S., South America, and Far East. Turning to the industrial sector, Italy was up 3%, Europe dropped 17% amid weakness in manufacturing, and non-European markets gained 8%. Andrea, please go ahead with the 2026 guidance.

Andrea Cangioli

executive
#5

Thank you, Enrico. I'll wrap up by commenting on the full-year outlook. Sales are still doing well, and we reaffirm our expectation of revenue growth above 5% for 2026. Profitability is heading in the right direction as well. Our guidance for improving the operating margin appears secure for the year, and that should let us finish 2026 with operating income of roughly EUR 90 million. Looking back over these nine months, I see a group that has achieved growth and a strong increase in profitability, while at the same time carrying out a profound transformation of its perimeter. Looking forward, I see a group that is more focused, more profitable and financially very strong, with a product portfolio customers want, an innovation pipeline ready to sustain our growth, and markets offering excellent long-term prospects. An aging population that wants to look and feel well, and medicine that increasingly calls for treatments that are less invasive and more effective. These trends play directly into our strengths. Our priorities for the months ahead are clear. First, continue bringing innovative products to market, beginning with the new systems I mentioned. Second, consolidate our presence in the U.S. and in the other fast-growing markets. Third, keep working on efficiency so that growth keeps translating into profitability. Fourth, invest in production capacity where demand calls for it, as we are doing with optical fibers manufacturing in Samarate. We will pursue these priorities with the same approach that has always set El.En apart: a long-term view, deep respect for technology, and a strong sense of responsibility toward all our stakeholders. Thank you for listening to our presentation. I believe at this point we have finished with the prepared remarks.

Carlo Maritano

analyst
#6

Hi, can you hear me?

Andrea Cangioli

executive
#7

Sure. Hi, Carlo.

Carlo Maritano

analyst
#8

Hello. Good afternoon, Andrea and Enrico. There are a few questions I'd like to ask. To start with, the EBIT margin was really quite striking, particularly during the third quarter. I was thinking about the medium term: do you believe an EBIT margin slightly below or close to 20% can be sustained, given that volumes and the installed base are rising, notably in certain segments? My next question also concerns capital allocation. Since you will additionally take in EUR 30 million from selling the cutting business, your financial position will sit above EUR 200 million. I wanted to ask whether the priorities have shifted at all or remain unchanged, and whether there is anything on the M&A side we might look at. Last, a question about the marking business, which continues to perform perhaps somewhat below expectations. I'd like to know what you can do to boost results in that division organically. Thank you.

Andrea Cangioli

executive
#9

Pardon me, Carlo. Which question came last? The industrial division, is that what you said?

Carlo Maritano

analyst
#10

Yes, specifically the marking business. What steps can be taken to enhance results organically, without any M&A or anything like that? Thank you.

Andrea Cangioli

executive
#11

EBIT margin. Naturally, we hope—and we strive—to keep the EBIT margin at such a high level. Naturally, three factors drive this record EBIT margin, even with the new perimeter. So disregarding what came before, and simply using the same consolidation perimeter as a benchmark. First, the product mix is favorable; thus we are selling a product mix that is favorable margin-wise. For instance, anti-aging products are more profitable than hair removal. Surgical products are more profitable on average than aesthetic ones. And that is for the margins. Second, efficiency; at Quanta System and at El.En., at DEKA, at Asclepion, we did substantial work aimed at lowering the cost of goods sold. And because of that, we succeeded. This is reflected in the margins, which stem partly from a more favorable mix but also from a cost reduction across the board. Then there is leverage. In this quarter, we had an interesting volume relative to the quarter—a quarter in which certain costs are also reduced because it is a slow quarter. In the end, we managed to capture this advantage deriving from the volume. Will we be able to replicate these results? That is our ambition. That is what we work for. That is what our expenditures today are directed toward. Today, we are successful; we have been successful in the past; we hope to be successful in the future. But naturally, we operate in a highly competitive environment; we are participants in a market where multiple players come from various parts of the world; now we have American players, Oriental players, players that are large corporations, players that are small local players disrupting our activities, so to speak, competing with our activities. Through our investment, we hope to keep our position ahead of the competition, and that is what we work toward. Naturally, there is no guarantee that our efforts, even though they are significant and have been well directed to date, will be able to replicate this performance going forward. Capital allocation. Again, this is something we attempt in order to strengthen our market position. Over these six months, I believe we have a great—excuse me, nine months. It is six because it operated for six months only. We had a great contribution from the new Quanta System subsidiary in the United States, which captured a portion of the margin that our distributor had been taking. Today, we are doing that job. We are obtaining that margin. This helps, naturally, in raising the overall margin. We are evaluating several small M&A transactions for certain specific segments. Nothing transformational. These are small transactions, and although they come through M&A, they could really be seen as an investment in our own internal capabilities and internal growth. So they resemble our traditional growth path, where we invest in our own capacity. Nothing here is new. Naturally, we only turned this page on November 5, which has been very demanding and has also weighed heavily on the overall management, on the general management of El.En. We finally managed to marry Cutlite Penta to the best bride we could ever imagine for them, the market leader, TRUMPF. Now perhaps we will have more time to evaluate various opportunities, including on the M&A side, and in any case to assess, as usual, all the opportunities for this group to keep growing the way it has in the past. The industrial business and the marking business, in fact, have not achieved the forecast growth so far this year. Our group mainly sells in Italy and Europe. We sell worldwide, but Italy and Europe are our main markets, and the target markets are linked to manufacturing. It is not the finest moment for the manufacturing world, the traditional manufacturing world; we are not tied too closely to the automotive world, but the automotive world is going through a deep transformation; we are closely tied to other market verticals; this year did not turn out to be a year of demand as we expected. That does not mean we are not continuing to invest in LASIT as well, which is the main player in our marking business. It does not mean we do not expect the business to expand in the future. This year, for now, will probably be a year in which, at the end of the year, we will need to confirm that no growth will be achieved over the year. But the technologies, the people in our organization, the projects are interesting, and I am optimistic that we can return, hopefully starting already from 2027, to the growth path that LASIT has followed to date. That is absolutely within the capabilities of this company, which has amazing technical capabilities and also a very important manufacturing plant, a very important logistics situation, which could allow it to grow faster in the future.

Carlo Maritano

analyst
#12

Thanks.

Andrea Bonfà

analyst
#13

Hello everyone, good afternoon. Is my voice coming through?

Andrea Cangioli

executive
#14

Yes. Andrea.

Andrea Bonfà

analyst
#15

Just quickly, a number of my questions have already been covered. Could you remind us what share of sales comes from the Middle East, or from the countries affected by the Gulf crisis, if that's possible? If you could expand a little on the new U.S. branch you opened, what would your targets be, so to speak, and your ambitions in that segment, urology in the U.S.? Finally, if I may, even though we don't have the exact 2025 EBIT pro forma required for a precise implied Q4 EBIT growth estimate, it seems to me that the EUR 90 million EBIT is somewhat conservative. There's surely room to do more. The same applies to net cash — after all, in last year's final quarter you brought in EUR 35 million, on top of EUR 30 million coming from the divestment of the metal laser cutting business. By the time the year closes, both EBIT and net cash could, let's say, end up looking quite strong. I'm not sure whether you could go into a bit more detail on that. Thanks. Apologies, and one last thing, Andrea — we parted ways after that earlier call in which you said that perhaps at some point next year, you might bring out a fresh MonaLisa Touch version featuring a new technology, if I'm recalling it right. If you could also give us an update, thank you.

Andrea Cangioli

executive
#16

All right. Let me see what I can answer. I don't have that memorized, and we've never shared precise regional sales volumes. We're speaking of a scale of roughly EUR 20 million across the Gulf region in total, all the companies combined, just under that, and this year saw a decline. Regarding the United States and the new facility, revenue came to around EUR 20 million this year; operations began on April 1st, so that's six months, seven months. Seven months it is. It was a strong contribution. Naturally, that isn't a full EUR 12 million in extra revenue, since inbound income factors in—yet it did add a few million to revenue and made a meaningful difference to EBIT and the EBIT margin. Next, you raised the topic of MonaLisa Touch, which came last. There was another question earlier, but I don't recall it—please restate that one for me. On MonaLisa Touch: we're taking another look at our CO2 portfolio. At present, Tetra PRO is the leading CO2 product in dermatology, whereas TRIO serves surgery; we're reexamining the CO2 lineup because, after several years, it requires a redesign and enhancements. On MonaLisa Touch specifically, there's no program in place. As of now, we haven't set up any investment plan to obtain FDA clearance for the complete MonaLisa application here in the United States, because our view is that the time and money required aren't necessarily so large — too large, rather — that it qualifies as an investment absolutely worth pursuing, at least not on our own. So far, nobody has come forward as a partner ready to put money in alongside us on that specific application. Right now, we see more upside in putting funds toward clearances for other products rather than bringing MonaLisa Touch back to life, though it is still an interesting product. EUR 20 million of revenue in 2020 is worth keeping in mind here. I'm quite sure a time will come when we can revive that product, with a new approach to clearance, marketing, and the technical side. Could you say your third question again — I'm sure I have it.

Andrea Bonfà

analyst
#17

That was about the implied potential for Q4 EBITDA.

Andrea Cangioli

executive
#18

Ah, yes, you're right. You're right; as usual we've been extremely conservative, extremely conservative. We hope the EUR 90 million threshold will be overcome, but we didn't want to exaggerate in the definition, excuse me, in guiding for results that we could not be able to achieve. You're right, the EUR 90 million, we should be easily, not easily, nothing is easy, but we should be in condition to get them without needing to have an extraordinary quarter. If we will have an extraordinary quarter, we will exceed that amount.

Andrea Bonfà

analyst
#19

And sorry, I just want to confirm I got this right — was it EUR 20 million in sales or EUR 12 million in sales that the urology branch in the U.S. brought in?

Andrea Cangioli

executive
#20

EUR 12 million — one, two. In seven months, EUR 12 million.

Andrea Bonfà

analyst
#21

All right. But would it be fair to think that, since this has only been running for seven months now, it could turn into a really significant growth engine if it continues climbing at this pace?

Andrea Cangioli

executive
#22

Partly, it's a substitution for revenue. We used to sell at a given price to a distributor, and today we're selling not to the end user — we're selling one step lower in the value chain to others, who aren't necessarily end users but are market participants along the urology market's value chain. Yes, I'm convinced this business could become a growth driver before long. It could, and it will have to evolve, because right now we have a very simple setup, one that doesn't involve a big sales and marketing investment but is mostly logistics support for certain large customers. Going forward, we might steer this platform toward a new approach to the business, one that brings us closer to the end user, growing the customer count and also growing the number of products we sell, and through that, growing our revenues further. That's something we aspire to. It isn't an outlined plan yet.

Andrea Bonfà

analyst
#23

Thanks a lot.

Valentin-Paul Jahan

analyst
#24

Good evening. Can you hear me clearly? Good afternoon, my apologies. Am I coming through okay?

Andrea Cangioli

executive
#25

Hello. Yes, Valentin, you come through clearly.

Valentin-Paul Jahan

analyst
#26

Right, that's great. From your 2026 guidance, it sounds like you're expecting a pretty cautious Q4 — can you give us more detail on how momentum is shaping up in Europe, country by country, where things are currently soft, and what's behind that caution?

Andrea Cangioli

executive
#27

Well, the guidance is really just a mathematical projection of our plans; there's no particular weakness on our side; demand in the Gulf area is still weak. As I mentioned in the prepared remarks, we're working to lift sales there through special market activities; we're seeing indications of a slowdown in the German market. In those comments, we noted that Germany and the DACH region has been one of the main growth drivers thanks to a highly effective distribution network. On the German market, we're getting a sense of slowdown. That's evident in the industrial segment, but it's also evident on the medical side; that's what we saw at the most recent exhibitions, which showed weaker demand and a weaker turnout of end users and business partners. Last year was extremely strong in medical, so we have to keep in mind that peak performances aren't guaranteed, particularly in December, which is one of the shortest months of the year in terms of working days, yet is typically the record setter for sales. Several conditions must be met for us to achieve sizable volumes or an exceptional outcome in December. We generally try not to count on an exceptional result. Last year, we had a very good result. If you simply replicate a very good result, you risk being a little too optimistic. CapEx came in at just EUR 11 million.

Valentin-Paul Jahan

analyst
#28

All right, thanks. And second, when you look past Q4, what's your view on how 2027 takes shape, especially those first few months? Is the cautious tone you mentioned for Q4 something tied to the year-end — like the December situation you described? Or do you think that caution extends into the first half of 2027?

Andrea Cangioli

executive
#29

Some markets right now are genuinely strong. Certain segments in Korea, in the Far East region, and also certain segments in the U.S. are performing very well indeed. With that in mind, we hold high hopes for the start of 2027 as well. That said, it's still a bit soon for us. We'll be putting together our 2027 budgets over the coming weeks. Actually, I will be — we aren't providing any 2027 guidance at this point. The sentiment right now is positive. It's ironic in a way. If we sell heavily in Q4, odds are Q1 comes in weaker. If we sell below our top expectation in Q4, odds are Q1 comes in stronger. The reason is that our sense is overall demand for our products is strong, and that strength should persist. Even if it sounds odd, we're 45 days out from year-end; it's hard to say how much of the backlog will actually ship and be billed before the year closes, since several factors affect that — and those same factors affect the first quarter of 2027 too. What I can say is we're confident a solid sales trend continues through both Q4 and the start of Q1.

Valentin-Paul Jahan

analyst
#30

All right, thanks.

Emmanuel de Figueiredo

analyst
#31

Hello, everyone.

Andrea Cangioli

executive
#32

Hey there.

Emmanuel de Figueiredo

analyst
#33

Am I coming through clearly?

Andrea Cangioli

executive
#34

Yes, Emmanuel. Hello there. It's good to hear from you.

Emmanuel de Figueiredo

analyst
#35

Hi, and thank you. To start, for the nine months of this year, could you shed some light on what portion of the revenue growth is driven by volumes and what portion by mix? Since mix is clearly much higher, meaning prices. That's my first question. My second question returns to 2027, which I realize is too early, but what probably isn't too early for you to address is which products you expect to contribute most to growth in 2027? And my last question is simply whether there's any update or anything important we ought to know regarding changes in top management, given that Paolo Salvadeo departed earlier this year. Thanks.

Andrea Cangioli

executive
#36

Alright. Let's start with the margins. My sense is that Q3 has a— well, we haven't crunched the numbers. I honestly don't know. What I mean is, I could work through the figures and then tell you — or anyone else who asks — how much of the EBIT margin movement came from volume and how much from mix. On top of that, I can say cost control was really solid in Q3; our expenses came in below what we had budgeted, which mattered a great deal and gave us a big lift. My take is that a strong mix effect was with us all year long, and in Q3, I'd say the volume effect was larger than it had been in the earlier months. Looking at 2027, the items we're relying on in urology are still the fibers. That's really significant. The fresh high-power holmium lasers—those resemble the Magneto; that's where we expect the large figures in the surgical space. For the smaller figures, though with the effect of a new offering, we're counting on this blue device we've just launched. It would be an interesting addition, I mean. We don't anticipate reaching tens of millions, but it would be a noteworthy new device. That covers surgery for me. Within aesthetics, Onda plus its Onda PRO evolution remain key bets for us; we intend to keep pushing innovation in microwave technology and applicators so that Onda increasingly becomes a facial rejuvenation tool. Recall that eight years back it launched as a body contouring system featuring a pocket handpiece? Later it became a skin tightening device. We're putting in the effort — we're not there yet — to add additional applicators, which will let the device increasingly serve as a tool for tightening skin and rejuvenating the face. We're also counting heavily on 2027 for a new iteration of the RedTouch laser system that's in development and slated to roll out over the course of the year. There are further long-term studies as well. The one I brought up in the prepared remarks involved ultra-short pulses, though I can't say for certain we'll secure the clearances needed to sell this product in 2027. That probably carries over into 2028. To keep it brief: fibers, Magneto, Onda PRO, RedTouch — these are the key items, the cornerstones, of what we expect to sell in 2027. On top management, the decision was clear that Paolo's position would not be replaced once he left. Paolo was central to many decisions, yet he also did an excellent job lifting the performance of a management layer that, after his departure, was promoted into a new organizational model with no single central pivot like the General Manager, but rather four individuals. I'm referring to the management of the El.En. In Florence, four individuals stepped up to lead sales, operations, industrial, and technical functions, and they report, in a manner of speaking, straight to the executive directors — to Gabriele and to me. That strikes me as a worthwhile balance. Of course, we don't have all of Paolo's insight and capabilities, yet the team is well balanced overall, and at present we see no need for a different setup.

Emmanuel de Figueiredo

analyst
#37

Thank you.

Andrea Cangioli

executive
#38

Okay, let me begin with the final question, and actually that last point isn't the situation; we aren't sitting on liquidity out of an expectation that the market will contract severely. I mean, we currently hold certain record levels of cash, but as our shareholders are aware, we have never been in a weak financial position; we're looking at additional investments and additional growth, first and foremost internally, and second through M&A, though not transformational; at this moment, certainly, no spending plan exists that would use up the entire net financial position. I explained this earlier when I responded, I think, to Carlo Maritano's question, and I reaffirm it now; likewise, at present we aren't planning any extraordinary cash distribution, but we do intend to assess strategic options carefully and calmly with the aim of improving our growth and our profitability, both by investing in our own operations and through small M&A that could complement our internal objectives.

Giovanni Selvetti

analyst
#39

Hi there, everyone. Am I coming through clearly to you?

Andrea Cangioli

executive
#40

Loud and clear, Giovanni.

Giovanni Selvetti

analyst
#41

Hello. My apologies — unfortunately I couldn't join for the opening portion of the conference, so I'm sorry in case some of my questions were already addressed, but I'll try anyway. I just wanted to ask whether the pickup we're seeing in surgical during Q3 is already partly reflected by Quanta launching its U.S. subsidiary. That's my first question. I'm certain you've already walked through the reasons the aesthetic segment decelerated in Q3. What I wanted to ask on that was, again, whether it's mostly connected to the drop in hair removal. Once more, apologies if that was raised earlier.

Andrea Cangioli

executive
#42

Giovanni, of course. That new subsidiary added a lot — it's clearly a factor behind the higher surgical segment sales. Exactly right. That's true now, it was true before, and we expect it to stay that way soon. Turning to aesthetics, several things are at play. Onda is a product that's really taking off; some of our other products could use a refresh — they've contributed plenty to growth but had gone somewhat flat recently. Mostly that's the CO2 lasers, which are up overall across the nine months but didn't grow notably last quarter, while hair removal keeps softening. I think hair removal is something we'll be looking into more closely soon. We have to figure out whether competing products are beating ours today—maybe because of performance we're not aware of, or possibly because of cost. We also need to determine if it's just a distribution issue, and whether having some—since we do have distributors for the aesthetic space, and we have such a successful product, or such a set of successful products like Onda, like RedTouch, with which, given the, let's say, defined sales capability of a particular distributor, we've seen them absorbed by this product. My view is that we also have to offer them something in hair removal—a category where, looking ahead, demand isn't forecast to shrink; it won't expand, yet it won't contract either. My sense is that we'll focus closely on bringing a fresh offering to hair removal as we head into 2027, and that should let us sidestep the revenue slippage we've seen over recent years.

Giovanni Selvetti

analyst
#43

All right, many thanks. Perhaps one more question about aesthetics. I noticed that across a number of, shall we say, posts on your, shall we say, pages on the different, shall we say, social platforms, LinkedIn and so forth, you seem to state that multiple copies of Onda exist, particularly in East Asia. I was wondering what steps you folks are taking so that a portion of the growth isn't lost to replicas or competitors that, in a sense, are presenting a similar product?

Andrea Cangioli

executive
#44

Yes, I've brought this up before. There are various types of copies and therefore various types of responses we can take, depending also on our protections, which are partly technical and partly tied to the brand. With regard to the Chinese copies, which claim to have a system that is Onda with performance matching ours, but which is essentially an empty system with no power, even though it looks like ours, it doesn't deliver any kind of emission suited to the use we provide with Onda. As you observed, we simply try to spread word of mouth that the systems are entirely different and that the customer must purchase the system from the original provider; we also dispatch cease and desist letters whenever and wherever we're able to determine where the machines originate, which isn't necessarily simple. Then there are other copies that are more subtle; they are copies in performance, they are copies in technologies, and we are pursuing the legal routes that must be pursued in these circumstances to protect ourselves from such copies. The good news here is that essentially we don't observe any inflection in the sales volume. Naturally, we don't know what the sales volume could be without these copies, but we have a certain tendency to regard those copy sales as an indicator of the device's success, and they represent a disturbance, but they also represent a, shall we say, celebration of the effectiveness and of the success of Onda. So, we are doing what needs to be done, but at this moment, we are not very concerned by this proliferation of copies.

Giovanni Selvetti

analyst
#45

Thank you.

Andrea Bonfà

analyst
#46

Hi, and thanks for fitting in my last question. I was reviewing how the services performed in medical aesthetic, and I noticed growth of 3.5%. We're aware that fiber optics for surgical applications typically grow at a healthy pace. From the outside, this result isn't clear-cut. Could you expand on that? Is it that fiber optics are growing double digit while other items grow less? If you could just elaborate on this point, thank you.

Andrea Cangioli

executive
#47

I don't believe we can say fiber optics grew double digit during the first nine months. In any case, we can say growth there was larger than the 3%, which is the total. That means the remaining revenues are growing less. There are a few elements. One is still the shortfall in Japan sales, which is worth, I believe, a couple of points, 1.5 points, the Japan sales. Then another, I believe, is sales, I mean, service in the hair removal area, which has seen a decline in sales of certain spare parts, notably the lamp. Raw amount of volume of sales for spare parts and time and material reduce slower growth. None of this concerns us. Just as an example, in the service activity in Italy, the sales activity-

Andrea Cangioli

executive
#48

It had generated during the initial year. There isn't any particular item, and there's no particular concern. We'll deal with this over the next months, should any need arise to deal with it in some way.

Andrea Bonfà

analyst
#49

Can you hear me, Andrea?

Andrea Cangioli

executive
#50

Yes.

Andrea Bonfà

analyst
#51

All right. We missed the second part of what you said, but we understand your point. Thanks a lot.

Andrea Cangioli

executive
#52

Thanks. Are you able to hear me at this point?

Andrea Bonfà

analyst
#53

Yeah, right, yeah. It got stuck for a bit there, which is why we missed what you said last. What you explained came through clearly.

Andrea Cangioli

executive
#54

Enrico. While Enrico pulls up that figure, I can mention that net profit was worked out using a constant tax rate assumption covering June through September, since for both the nine months and the three months interim reporting we aren't required to report all the way down to net profit, but purely to provide some information, as Enrico mentioned in his presentation, we did the calculation. Enrico

Enrico Romagnoli

executive
#55

Yeah, sorry about that. Right. We only ran this exercise covering the nine months, which means we don’t have the Q3 net result; across those nine months, the figures are EUR 41 million for 2026 and EUR 36 million for 2025. The reason is that, as is normally the case, the quarterly report doesn’t display the final line of the profit and loss.

Andrea Cangioli

executive
#56

<<foreign_lang>>

Enrico Romagnoli

executive
#57

Suppose we hadn't worked out the income taxes for, let me check, hold on a moment.

Andrea Cangioli

executive
#58

So, assuming the financials are right — and I take them to be — net profit before third parties came to EUR 27.2 million in June. So, I mean

Enrico Romagnoli

executive
#59

Andrea, I didn't check this number.

Andrea Cangioli

executive
#60

Okay.

Enrico Romagnoli

executive
#61

I would like to avoid to give

Andrea Cangioli

executive
#62

a wrong communication.

Enrico Romagnoli

executive
#63

misleading information.

Andrea Cangioli

executive
#64

Perhaps if Roberto could share his surname and a reference too, then we’d be able to give him that answer separately, at a later point. All right?

Enrico Romagnoli

executive
#65

I just want to finish up, since I checked the figure in the meantime. Net income for Q3 2026 came in at EUR 15 million, versus EUR 18 million. Keep in mind that the discontinued operation had a negative impact in Q3 2026, whereas its contribution was positive in Q3 2025. If you exclude the discontinued operation from both Q3 2025 and Q3 2026, net income from continuing operations — and this is only an estimate — is EUR 18 million in 2026 and EUR 14.8 million in 2025, which works out to an increase of 22%. The discontinued operation has a meaningful impact-

Andrea Cangioli

executive
#66

Yeah, what-

Enrico Romagnoli

executive
#67

on the quarterly figures.

Andrea Cangioli

executive
#68

So the key takeaway is this: when you look at net profit overall, discontinued operations have to be factored in too. Discontinued operations did badly in 2026, and Q3 2026 in particular was extremely weak — that quarter was really poor. The old cutting business's results dragged down the net result, meaning the consolidated net result for that quarter. Naturally, excluding that, the rest of the business did considerably better, with the medical business standing out in particular, and that drove the quarter-over-quarter gain in net profit.

Andrea Cangioli

executive
#69

Thank you.

Enrico Romagnoli

executive
#70

Bye-bye.

Operator

operator
#71

Bye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.